Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Kanyr Pharma Inc. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. KIM, TAEYOON is the busiest examiner for the portfolio, handling this 1 pending action. The prosecution involves 1 distinct examiner and 1 distinct art unit. This indicates that the company's active patent interest is currently focused on a single examination process.
With 1 pending office action assigned to KIM, TAEYOON, the company's prosecution is concentrated under a single examiner. This arrangement within the Biotechnology & Pharmaceuticals sector means that the outcome of the current filing depends entirely on the review within 1 distinct art unit. For the company, having 1 distinct examiner simplifies the management of its pending matters but also means there is no diversification across different examiners. The presence of 1 pending action for the busiest examiner confirms that the entire active portfolio is currently being reviewed by the same individual.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIM, TAEYOON | 1 | 51.4% | +52.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18707198 | PHOSPHATASE INHIBITORS AS NK CELLS MODULATORS FOR THE TREATMENT OF CANCER | KIM, TAEYOON | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18707198 | PHOSPHATASE INHIBITORS AS NK CELLS MODULATORS FOR THE TREATMENT OF CANCER | KIM, TAEYOON | — |
| Art Unit | Apps |
|---|---|
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18707198 | PHOSPHATASE INHIBITORS AS NK CELLS MODULATORS FOR THE TREATMENT OF CANCER | KIM, TAEYOON | 1631 | §103§112 | Non-Final OA | — | Pending | May 03, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialKanyr Pharma Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Taeyoon Kim has the most, with 1 of Kanyr Pharma Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
